RecruitingPhase 1NCT07247266

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

A Phase 1b, Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Sponsor

Akros Pharma Inc.

Enrollment

5 participants

Start Date

Feb 2, 2026

Study Type

INTERVENTIONAL

Conditions

Cryopyrin-associated Periodic Syndromes (CAPS)

Summary

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JTE-162 for people with cryopyrin-associated periodic syndromes (caps). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJTE-162

Tablets containing JTE-162

Locations(1)

Gordon Sussman Clinical Research Inc.

North York, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07247266

Related Trials

Ilaris NIS in Korea

NCT068381431 location